Drug Trial Radar · NCT02791230
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,733
Actual
Start
Jun 13, 2016
Primary completion
Oct 26, 2023
Study completion Nov 2, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
TafamidisDrug
Soft gel capsules administered once a day for 60 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to All-Cause Mortality: Cohort ATime frame: From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]
- Number of Participants With All-Cause Mortality Events: Cohort BTime frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
- Number of Participants With Treatment-Emergent Adverse Events (AEs)Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Locations
80 sites in 17 countries. Site status is shown where the registry gives one.
The Kirklin Clinic of UAB Hospital
Birmingham, Alabama
Cardiovascular Clinical Trials Unit (CCTU)
Birmingham, Alabama
University Hospital, University of Alabama at Birmingham
Birmingham, Alabama
California Heart Center
Beverly Hills, California
Cedars-Sinai Medical Care Foundation
Beverly Hills, California
Altman Clinical Translational Research Institute
La Jolla, California
University of California, San Diego
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California, San Diego Medical Center - Hillcrest
San Diego, California
Center Adv Lab Medicine
San Diego, California
UCSF Ambulatory Care Center
San Francisco, California
University of California
San Francisco, California
UCSF Cardiovascular Care and Prevention Center
San Francisco, California
Stanford University Hospital and Clinics
Stanford, California
Sylvester at Deerfield Beach
Deerfield Beach, Florida
University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center
Miami, Florida
Northwestern Medical Group
Chicago, Illinois
Northwestern Memorial Hospital
Chicago, Illinois
Advocate Christ Medical Center
Oak Lawn, Illinois
University of Maryland, Baltimore
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Boston Medical Center Investigational Pharmacy
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
Michigan Medicine,University of Michigan
Ann Arbor, Michigan
Mayo Clinic Hospital-Rochester
Rochester, Minnesota
Mayo Clinic
Rochester, Minnesota
Newark Beth Israel Medical Center
Newark, New Jersey
NYU Langone Health
New York, New York
Center for Advanced Cardiac Care
New York, New York
Columbia University Irving Medical Center
New York, New York
Duke University
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
OHSU Center for Health and Healing
Portland, Oregon
OHSU Research Pharmacy Services
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Vanderbilt Univ. Med. Ctr
Nashville, Tennessee
Huntsman Cancer Hospital
Salt Lake City, Utah
University of Utah Hospitals & Clinics
Salt Lake City, Utah
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.